More New FDA Warning Letter because of inadequate Quality Oversight
More Two FDA Warning Letters: Identity Testing of Incoming Components
More Cleanroom Pressure Control: Where should the 0 Reference be measured?
More FDA seeks Participants for the next Phase of the Quality Manufacturing Maturity Programme
More FDA Office of Compliance - Annual Report FY 2023 Published
More New Ph. Eur. Chapter Comparability of Alternative Analytical Procedures
More Use of Digital Health Technologies (DHTs) to Acquire Data Remotely
More FDA Exception from the Requirement to obtain Informed Consent
More EMA recommends Suspension of Medicines following GCP Inspection of a CRO in India
More Revision of USP Chapter <1053> Capillary Electrophoresis Published for Comments
More Checklist for Implementation of GDP Principles - Part 3: Premises and Equipment
More Failure to Respond to Multiple FDA Requests leads to Warning Letter
More FDA Warning Letter to Turkish Manufacturer of Drugs, Cosmetics and Detergents
More Cloud Computing: Can an automated Deployment Chain replace an IQ?
More Now Available: Reference Standards for the new Ph. Eur. Cannabis/CBD Monographs